Description
This study evaluatated transcriptomic changes in RNA isolated from whole-blood samples from 12 patients receiving different doses of Varlilumab at several different time points following treatment. The aim of this study was to determine the extent to which expression of inflammatory molecules changes over time in response to treatment with Varilumab, a fully human monoclonal antibody (mAb) that targets CD27.